Biological agents for chronic wounds

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.

Original languageEnglish (US)
Pages (from-to)23-25
Number of pages3
JournalAmerican Journal of Clinical Dermatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 9 2010

    Fingerprint

ASJC Scopus subject areas

  • Dermatology

Cite this